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Abstract
TB education and counseling (TEC) is universally recommended for individuals initiating
treatment for active TB in Uganda. The effectiveness of routine TEC in Kampala and the
association between specific knowledge domains and treatment outcomes is unknown. We
sought to (1) to evaluate the effectiveness of routine TEC in helping individuals to increase and
retain TB-specific knowledge and (2) to examine the association between TB knowledge and
treatment outcomes among individuals diagnosed with TB. We enrolled adults (age ≥18)
initiating treatment for active TB at Kisenyi Health Centre in Kampala, Uganda into a
prospective, observational cohort study. We administered a verbal survey before and after TEC
and at three refill appointments. We analyzed change in knowledge at three hierarchicallyorganized levels. We used Poisson and logistic regression models to describe associations with
nonadherence and final treatment outcome, respectively. Eighty patients were enrolled. After
TEC, TB disease-specific and treatment-specific knowledge increased significantly overall and
across each of the eight sub-domains. Nine of 17 disease-specific questions and 11 of 13
treatment-specific questions changed significantly after TEC. For disease-specific knowledge,
scores did not change significantly at two of three follow-up interviews; for treatment-specific
knowledge, scores did not change significantly at any of the follow-up interviews. Disease- and
treatment-specific scores were significantly associated with nonadherence at two weeks and two
months. At least two of the eight sub-domains were significantly associated with nonadherence
at each time point. Routine TEC was effective at increasing knowledge, and this knowledge
was generally retained. Individual question scores were heterogeneous and show where TEC can
be improved. Further, domains associated with nonadherence provide insight into areas where
TB knowledge may be most important and where TEC should be targeted in future interventions.
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Tables
Table 1. Study participant characteristics
Characteristic
Sex
Male
Female
Age
<29
30-39
40-49
>50
Occupation
Self-employed
Formally employed
Not employed
Student
Education
No schooling at all
Literacy classes only
Some primary school
Completed primary school
Some secondary school
Completed secondary school
Higher education
HIV Status
Positive
Negative
Previous TB Status
Yes
No
TEC Type
Group
Individual
Received TEC with Visual Aid
Yes
No
TB Diagnosis
GeneXpert
Sputum smear microscopy
Clinical diagnosis
Extrapulmonary
Data missing

Frequency (n=80)

Percent

58
22

73%
28%

38
23
16
3

48%
29%
20%
4%

36
27
15
2

45%
34%
19%
3%

5
2
23
19
20
5
6

6%
3%
29%
24%
25%
6%
8%

29
51

36%
64%

24
56

30%
70%

43
37

54%
46%

45
35

56%
44%

56
2
17
4
1

70%
3%
21%
5%
1%
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47
(36-59)
49
(44-54)
54
(48-61)
71
(66-76)
77
(72-83)

Pre-Test Mean
(95% CI)
(%)

75
(69-81)
74
(69-79)
96
(94-98)

83
(74-91)
65
(60-70)
69
(63-74)
80
(76-84)
85
(81-89)

Post-Test Mean
(95% CI)
(%)

54
(47-62)
42
(37-47)
24
(20-29)

35
(22-48)
16
(8-23)
14
(8-21)
9
(3-14)
7
(2-13)

Difference
(95% CI)
(%)

<0.0001

p-value2

<0.0001

<0.0001

<0.0001

0.0087

0.002

0.0001

<0.0001

20
(14-27)
32
(27-37)
72
(67-76)

Table 2. Knowledge content domains: within-patient difference of means
Content Domain1
Disease-Specific Knowledge
Prevention
Microbiology
Transmission
Warning signs
TB vs HIV
Treatment-Specific Knowledge
Treatment monitoring
How to take medications
How treatment works

1
Content
domains are listed in descending order of magnitude of difference within each construct
for dependent t-test of difference in means
2p-value
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Question
TB attacks the lungs*
TB can attack other parts of the body outside of the lungs*
Everyone who is exposed to TB germs does not become ill*
A cough that does not go away for two weeks is a warning sign of TB*
A cough that goes away after a few days not is a warning sign of TB*
Loss of weight is a warning sign of TB*
General weakness is a warning sign of TB*
Vomiting is not a warning sign of TB*
TB can be spread through the air*
How are TB germs released?
If you breathe in TB germs, where do they settle and grow?
TB cannot be spread through food*
TB cannot be spread through drinking water*
Can you have HIV only (without TB)?
Can you have TB only (without HIV)?
Unprotected sex cannot spread TB*
How can you stop the spread of TB?

Table 3. TB disease-specific knowledge individual question scores
Content Domain
Microbiology

Warning signs

Transmission

TB vs HIV
Prevention

*Question was answered in a “Yes/No” format
1p-value for McNemar’s test
(Italicized questions have sub-optimal post-test scores)
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Pre
87%
34%
30%
88%
82%
91%
57%
46%
99%
60%
47%
39%
32%
92%
90%
50%
49%

Post
96%
68%
31%
96%
93%
90%
64%
56%
98%
86%
71%
46%
41%
99%
99%
58%
83%

p-value1
0.01
<0.0001
0.85
0.03
0.04
1.00
0.10
0.05
1.0
<0.0001
0.0002
0.32
0.10
0.06
0.02
0.30
<0.0001

Question
How often can TB be cured if treatment is started in time?
When do you take your TB medications?
If you stop treatment before the full course of therapy, your TB becomes harder to
cure*
If you stop taking the TB medication before the treatment period is finished, what
might happen?
When can you stop taking the TB medication?
What do your TB medications look like?
If you have TB, how long do you take the medication?
What should you do if your TB medication gives you yellow or red eyes, too much
vomiting, intense body rash, or issues with sight?
What should you do if your TB medication gives you joint pain?
Name two potential side effects of TB treatment
What should you do if your TB medication gives you nausea?
When should you come to the clinic for your next appointment?
After starting the medication, how long does it usually take to start feeling better?

Table 4. TB Treatment-specific knowledge individual question scores
Content Domain

How treatment
works

How to take
medications

Treatment
monitoring

*Question was answered in a “Yes/No” format
1
p-value for McNemar’s test
(Italicized questions have sub-optimal post-test scores)
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31%
5%
26%
11%
31%

55%

51%
26%
53%

93%

96%

Pre
91%
27%

56%
65%
44%
95%
54%

89%

89%
96%
91%

96%

96%

Post
100%
99%

<0.0001
<0.0001
0.001
<0.0001
0.0001

<0.0001

<0.0001
<0.0001
<0.0001

0.48

1.0

p-value1
0.008
<0.0001

Construct
DiseaseSpecific
TreatmentSpecific
for dependent t-test of difference in means

Time Point
Two weeks
Two months
Five months
Two weeks
Two months
Five months

Mean Change
-1.2%
-10%
-2.9%
+2.6%
-3.0%
-3.6%

Table 5. TB knowledge retention in relation to post-test at diagnosis

1p-value

95% CI
-5.1% to +2.7%
-15% to -5.7%
-7.1% to +1.3%
-2.5% to +7.7%
-7.6% to +1.5%
-8.7% +1.4%
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p-value1
0.54
<0.0001
0.17
0.31
0.19
0.15

Number of
patients
reporting (n)
73
67
54

Mean
number of
days
2.1
1.2
0.78

Table 6. Self-reported nonadherence over the last week
Appointment
Two weeks
Two months
Five months

Standard
deviation
1.9
1.6
1.5

1
22
16
11

2
21
9
9

Percent missing x number of doses in last
week (%)
3
4
5
6
7
15 8
5
3
4
16 4
1
0
1
2
7
0
0
2
0
22
51
69
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Table 7. Self-reported difficulties with treatment
Experience
Felt worse after taking pills
Forgot to take pills
Ran out of pills
Was away from home
Too busy
Had trouble taking pills at specified times
Was confused about how to take pills

Two weeks,
n=73

Mean (%)
43
4.3
7.1
10
2.9
59
7.1

Standard
Error (%)
6.0
2.4
3.1
3.6
2.0
5.9
3.1

Two months,
n=67

Mean (%)
24
1.5
9.1
4.5
0
26
1.5

Standard
Error (%)
5.3
1.5
3.6
2.6
0
5.4
1.5
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Five months,
n=54

Mean (%)
11
5.5
11
0
0
15
0

Standard
Error (%)

4.2
3.1
4.2
0
0
4.8
0

Two weeks, n=73

IRR
(95% CI)
0.86
(0.76-0.98)
0.95
(0.89-1.02)
0.96
(0.89-1.05)
0.92
(0.85-0.98)
0.94
(0.86-1.03)
1.00
(0.96-1.04)
0.88
(0.80-0.97)
0.87
(0.73-1.04)
0.90
(0.84-0.96)
0.96
(0.91-1.02)
0.20

0.001

0.13

0.01

0.83

0.12

0.01

0.36

0.16

0.02

p-value1

Two months, n=67

IRR
(95% CI)
0.82
(0.67-0.97)
0.98
(0.90-1.08)
0.94
(0.83-1.05)
0.87
(0.79-0.97)
0.98
(0.86-1.11)
0.97
(0.92-1.02)
0.80
(0.70-0.90)
0.85
(0.66-1.09)
0.89
(0.81-0.97)
0.88
(0.81-0.94)

0.001

0.01

0.21

<0.0001

0.25

0.74

0.01

0.26

0.73

0.02

p-value1

Five months, n=54

IRR
(95% CI)
0.93
(0.73-1.20)
0.87
(0.76-0.99)
1.19
(0.99-1.43)
0.90
(0.78-1.03)
0.87
(0.74-1.03)
1.07
(0.96-1.18)
0.99
(0.83-1.19)
1.82
(1.01-3.28)
0.97
(0.85-1.11)
0.98
(0.88-1.09)

0.72

0.66

0.05

0.95

0.22

0.10

0.14

0.07

0.04

0.58

p-value1

Table 8. Bivariate associations between knowledge measures (scaled 0-10) and self-reported non-adherent days in the last week
Variable
Disease-specific
Microbiology
Warning signs
Transmission
TB vs HIV
Prevention
Treatment-specific
How treatment works
How to take meds
Treatment monitoring

p-value for bivariate Poisson regression test

1
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1.09
(0.99-1.20)
2.01
(1.46-2.76)
0.76
(0.31-1.86)
2.10
(1.37-3.22)
1.67
(1.11-2.54)
2.81
(1.70-4.65)
1.75
(1.25-2.47)
1.43
(0.84-2.43)

0.88
(0.62-1.26)
1.01
(1.00-1.03)
1.30
(0.94-1.79)
0.70
(0.48-1.01)
0.84
(0.61-1.15)
0.81
(0.59-1.11)

Two weeks, n=73
IRR (95% CI)

0.19

0.001

<0.0001

0.02

0.001

0.55

<0.0001

0.10

0.19

0.27

0.06

0.11

0.15

0.49

p-value1

3.5
(2.25-5.44)
2.60
(0.81-8.15)

--

1.00
(0.86-1.16)
1.62
(1.02-2.58)
1.69
(0.42-6.89)
3.25
(1.99-5.31)
1.42
(0.58-3.52)

0.78
(0.47-1.3)
0.98
(0.96-1.01)
1.15
(0.73-1.80)
0.43
(0.23-0.77)
1.52
(0.97-2.40)
1.31
(0.82-2.10)

Two months, n=67
IRR (95% CI)

Five months, n=54
IRR (95% CI)

1.80
(0.98-3.30)
0.99
(0.95-1.02)
0.94
(0.50-1.78)
0.90
(0.47-1.72)
0.77
(0.42-1.41)
1.27
(0.67-2.42)

p-value1

0.06

0.38

0.86

0.74

0.39

0.46

<0.0001

0.26

0.02

--

0.45

2.30
(1.18-4.49)

--

--

--

0.02

--

--

<0.0001

<0.0001

--

1.59
(1.28-1.96)
1.60
(0.71-3.60)
2.83
(1.19-6.72)
4.92
(2.64-9.18)

0.11

<0.0001

0.46

0.04

0.99

0.26

0.07

0.005

0.55

0.18

0.34

p-value1

Table 9. Bivariate associations between demographic measures, clinical measures, and intermediate treatment variables and selfreported non-adherent days in the last week
Variable
Demographic/Clinical Measures
Female2
Age3
Person living with HIV2
Prior history of TB2
Individual counseling2
Completed primary school2
Intermediate treatment variables
Number of late appointments3
Felt worse after taking the pills2
Forgot to take the pills2
Ran out of pills2
Was away from home2
Too busy2
Trouble taking pills at specified times2
Confused about how to take pills2
1p-value for bivariate Poisson regression test
2Binary variable
variable
variable (range: 0-6)
3Continuous

4Count

15

--1.3 (0.94-1.8)
----

-0.91 (0.85-0.98)
--

--0.93 (0.87-1.0)
---

Two weeks, n=73
Adjusted IRR (95%
CI)

--0.12
----

-0.008
--

--0.04
---

pvalue1

---0.52 (0.28-0.96)
1.6 (1.0-2.5)
--

--0.90 (0.84-0.97)

--0.92 (0.83-1.0)
---

Two months, n=67
Adjusted IRR (95%
CI)

---0.04
0.05
--

--0.008

--0.13
---

pvalue1

2.0 (1.1-3.8)
------

1.6 (0.85-2.9)
---

0.88 (0.77-1.0)
1.2 (0.96-1.5)
-0.82 (0.68-0.98)
--

Five months, n=54
Adjusted IRR (95%
CI)

0.03
------

0.15
---

0.05
0.11
-0.03
--

pvalue1

Table 10. Multivariate adjusted associations with self-reported nonadherence

Variable
Disease-specific
Microbiology
Warning signs
Transmission
TB vs HIV
Prevention
Treatment-specific
How treatment works
How to take meds
Treatment monitoring
Demographic/Clinical Measures
Female
Age
Person living with HIV
Prior history of TB
Individual counseling
Completed primary school
p-value for coefficient in multivariate Poisson regression test

1
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Table 11. Frequency of patients classified under each final treatment outcome
Outcome
Treatment completed
Died
Lost to follow up
Treatment failed

Frequency (n=80)
49
2
17
4

%
68
2.8
24
5.6

Coding for analysis
Completed treatment
Did not complete
treatment

17

2.6
1.9

18%
31.0
41%
18%
32%
59%
2.45

Mean
(Did not
complete
treatment)
75%
65%
80%
63%
87%
78%
81%
97%
73%
72%

1.8
1.0

33%
31.5
31%
37%
55%
61%
1.53

76%
63%
80%
71%
85%
82%
82%
96%
74%
76%

Mean
(Completed
treatment)

0.78 (0.58-1.06)
0.72 (0.49-1.04)

2.30 (0.67-7.90)
1.01 (0.96-1.07)
0.69 (0.24-1.93)
2.76 (0.81-9.39)
2.81 (0.98-8.03)
1.02 (0.37-2.80)
0.69 (0.50-0.96)

1.11 (0.74-1.66)
0.96 (0.77-1.20)
0.99 (0.75-1.30)
1.17 (0.95-1.46)
0.94 (0.70-1.25)
1.02 (0.90-1.15)
1.04 (0.76-1.44)
0.85 (0.45-1.61)
1.01 (0.80-1.26)
1.05 (0.88-1.26)

OR (95% CI)

0.11
0.08

0.19
0.70
0.48
0.10
0.06
0.98
0.03

0.61
0.73
0.93
0.14
0.66
0.74
0.79
0.62
0.96
0.59

p-value1

Table 12. Bivariate associations with final treatment outcome
Variable
Disease-specific knowledge
Microbiology
Warning signs
Transmission
TB vs HIV
Prevention
Treatment-specific knowledge
How treatment works
How to take medications
Treatment monitoring
Demographic/Clinical Measures
Female
Age (years)
Persons living with HIV
Prior history of TB
Individual counseling
Completed primary school
Number of appointments late
Self-reported nonadherence
Two weeks (days over last week)
Two months (days over last week)
p-value for bivariate logistic regression test

1
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Table 13. Multivariate adjusted associations with final treatment outcome
Variable
Disease-specific knowledge
Microbiology
Warning signs
Transmission
TB vs HIV
Prevention
Treatment-specific knowledge
How treatment works
How to take medications
Treatment monitoring
Demographic/Clinical Measures
Female
Age (years)
Persons living with HIV
Prior history of TB
Individual counseling
Completed primary school

Adjusted OR (95% CI)

p-value1

--1.18 (0.94-1.49)
---

--0.16
---

----

----

2.40 (0.67-8.65)
---2.73 (0.93-8.02)
--

0.18
---0.07
--

p-value for bivariate logistic regression test

1
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Figure 1. TB treatment timeline at Kisenyi Health Centre
(Study interview points indicated by numbered boxes)

Figures
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Figure 2. Schematic delineating the two constructs and eight content domains of TB knowledge
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Figure 3. Results of screening and enrollment process

22

Figure 4. Mean TB knowledge content domain scores before and after TEC

23

Figure 5. Mean TB disease-specific individual question scores before and after TEC (Question legend on next page)
Block 1: Pre-test and post-test score are below 90%
Block 2: Pre-test score is below 90%/post-test score is above 90%
Block 3: Pre-test and post-test score are above 90%
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Figure 5 Question Legend
Block

1

2

3

Question Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Question
Everyone who is exposed to TB germs does not become ill
TB cannot be spread through drinking water
TB cannot be spread through food
Vomiting is not a warning sign of TB
Unprotected sex cannot spread TB
General weakness is a warning sign of TB
TB can attack other parts of the body outside of the lungs
If you breathe in TB germs, where do they settle and grow?
How can you stop the spread of TB?
How are TB germs released?
A cough that goes away after a few days is not a warning sign of TB
TB attacks the lungs
A cough that does not go away for two weeks is a warning sign of TB
Loss of weight is a warning sign of TB
TB can be spread through the air
Can you have HIV only (without TB)?
Can you have TB only (without HIV)?
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Figure 6. Mean TB treatment-specific individual question scores before and after TEC (Question legend on next page)
Block 1: Pre-test and post-test score are below 90%
Block 2: Pre-test score is below 90%/post-test score is above 90%
Block 3: Pre-test and post-test score are above 90%
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12

11

7
8
9
10

6

3
4
5

2

Question Number
1

Figure 6 Question Legend
Block

1

2

3
13

Question
What should you do if your TB medication gives you nausea?
After starting the medication, how long does it usually take to start
feeling better?
What should you do if your TB medication gives you joint pain?
Name two potential side effects of TB treatment
When can you stop taking the TB medication?
What should you do if your TB medication gives you yellow or red
eyes, too much vomiting, intense body rash, or issues with sight?
If you have TB, how long do you take the medication?
When should you come to the clinic for your next appointment?
What do your TB medications look like?
When do you take your TB medications?
If you stop treatment before the full course of therapy, your TB
becomes harder to cure
If you stop taking the TB medication before the treatment period is
finished, what might happen?
How often can TB be cured if treatment is started in time?
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Introduction
Tuberculosis (TB) is one of the largest contributors to global mortality and recently
surpassed HIV as the leading cause of death from a single pathogen [1]. In 2014, the member
states of the World Health Organization (WHO) and the United Nations (UN) signed on to the
WHO’s END TB Strategy, which calls for large reductions in global TB mortality and incidence
by 2030 [1]. In 2017, it was estimated that 10 million incident active TB cases occurred
globally, with 25% of these occurring in the WHO African Region [1]. While the global TB
disease incidence rate is steadily falling at around 2% per year, the rate of decline is not
sufficient to meet the END TB Strategy goal of 4-5% per year by 2020 [1, 2]. Additionally, the
END TB Strategy calls for a reduction of the global TB case fatality ratio to 10% by 2020; in
2017, this number was still at 16% [1, 2]. What must be done, then, to achieve the END TB
Goals? In addition to structural changes at the policy and health system level and research into
new treatments and prevention strategies, the END TB Strategy states that existing interventions
must be expanded and streamlined to focus on high-impact and patient-centered approaches [2].
With timely diagnosis and treatment, active drug-susceptible TB disease can be easily
cured [1]. Despite this, in low- and middle-income countries with a high burden of TB disease
and death, poor adherence to TB treatment persists. Poor adherence has been shown to result in
both a decline in treatment effectiveness and the development of antimicrobial resistance [3, 4].
In Uganda, 25,000 people died from TB in 2017, and the most recent data show that 1.6% of new
TB cases in the country are resistant to at least rifampin, the most effective first-line drug for TB
[1]. The specific impact of partial nonadherence was demonstrated in a recent pooled analysis of
three clinical trials of novel 4-month treatment regimens [5]. Compared to those who did not
miss a single dose, participants who missed approximately one dose per week had 2.4-fold

28

increased risk of unfavorable outcomes, and those that missed two doses per week had 29 times
the risk of unfavorable outcomes compared to those who did not miss any doses [5].
A systematic review of qualitative studies uncovered a number of broad themes that may
influence adherence [3]. While some factors such as poverty and gender discrimination can
reduce treatment adherence even in patients willing to adhere, the review discerned a number of
factors that could be directly attributed to individual patient factors, including knowledge and
beliefs about TB and its treatment [3]. Patient knowledge can interact with structural and health
care service factors (e.g. drug stock-outs, long wait times and transport difficulties) as well as
social factors (e.g. stigma and motivation to complete treatment) to either encourage or dissuade
adherence [3]. Uganda is one of 20 countries that account for 83% of global incident TB disease
cases among people living with HIV (PLHIV), and HIV status has also been documented as a
potential risk factor for nonadherence [1, 3]. The complex nature of these determinants suggests
a need for more patient-centered approaches to promote positive treatment outcomes [3]. To this
end, Pillar One of the END TB strategy calls for a focus on integrated, patient-centered care and
prevention, and specifically states that “patient-centered care and support, sensitive and
responsive to patients’ educational, emotional and material needs, is fundamental to the new
draft global tuberculosis strategy” [2]. We hypothesize that a combination of patient-centered
interventions will be necessary to address different barriers to adherence, including TB
knowledge and beliefs, TB-related stigma, and TB treatment intentions. One intervention that
has been utilized in this effort is patient TB education and counseling (TEC) delivered by health
workers. TEC aims to increase patient knowledge around TB disease and treatment, ensure that
the patient understands the outcomes associated with adherence behavior, and provide the patient
with a sense of self-efficacy to adhere to medication and complete treatment [6].
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It is universally advised that TEC be administered to individuals initiating treatment for
active TB. The WHO guidelines for treatment of drug-susceptible TB strongly recommend
health education for all patients initiating treatment, with this intervention specifically defined as
a method of encouraging treatment adherence [7]. There is evidence that TEC may be important
in influencing positive treatment outcomes when combined with a larger set of patient-centered
adherence interventions, including reminders, incentives, and digital technologies such as SMS
messages and video-observed therapy (VOT) [6]. A systematic review and meta-analysis of
studies examining the impact of these adherence interventions found three randomized controlled
trials and one cohort study that demonstrated an association between TEC and increased rates of
treatment adherence, completion, and cure [6, 8-11]. However, the nature of the interventions in
these studies focused either exclusively on psychotherapy or on education related to treatment
processes [8-11]. Additional studies on the independent effect of patient education and
counseling on medication adherence have been sparse in number and have generally focused on
treatment for latent TB [12]. There is a gap in the literature examining the independent impact of
TEC interventions that focus on adherence counseling. Furthermore, there is a lack of studies
evaluating the effectiveness of TEC in delivering education around both TB disease and
treatment.
Previous studies have examined the association between TB knowledge and a variety of
outcomes. Two cross-sectional studies in Ethiopia found associations between TB knowledge
and health-seeking behavior [13, 14]. Additionally, a cross-sectional study in Nigeria found that
unsatisfactory knowledge was associated with patient delay in treatment initiation, and a casecontrol study in Morocco found that poor knowledge resulted in an increased risk of defaulting
from treatment [15]. There is reason to believe that TB knowledge influences a number of
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treatment outcomes, but the specific domains of knowledge that drive this association are
unknown.
We found only one study that conducted an evaluation of routine TEC prescribed by the
country’s National TB Program, which took place in Vietnam [16]. While TEC is universally
recommended, the effectiveness of its implementation in practice has not been systematically
evaluated. Previous qualitative studies conducted in Kampala with patients and health workers
highlighted that there was a perceived importance placed on TEC in encouraging patient
adherence, but there was a need for improvements in routine TEC administered to patients [17,
18]. This project seeks to determine if routine practice is effective in increasing TB disease and
treatment knowledge, and, if so, which aspects are associated with favorable TB treatment
outcomes. We conducted this study as part of a larger assessment of individual-level barriers to
treatment adherence. The results of the project will inform the development of a tailored
adherence intervention to be piloted in Kampala.
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Methods
Study Design and Setting
We performed a prospective cohort study to describe the antecedents of TB treatment
behaviors and their associations with outcomes among adult patients receiving treatment for
active TB in Kampala, Uganda. The study was conducted at Kisenyi Health Centre, an urban,
public, primary health clinic operated by the Kampala Capital City Authority (KCCA) on behalf
of the Ugandan Ministry of Health (MoH). At Kisenyi Health Centre and other similar clinics
nationwide, the Uganda National TB and Leprosy Programme (NTLP) offers free TB diagnosis
and treatment services in dedicated TB Units with WHO-approved, short-course treatment
regimens through community-based directly observed therapy [7]. Laboratory technicians
employed by KCCA perform on-site diagnostic testing using GeneXpert molecular testing and
sputum smear microscopy. Full-time KCCA nurses dispense medications. Generally, TEC is
administered by part-time community health workers (CHWs) rather than by clinicians. This
task-shifting adaptation was introduced by external implementing partners who provide technical
assistance with USAID funding. Through this mechanism, CHWs are employed to conduct
contact investigation and other TB programmatic activities.
The Uganda NTLP recommends TB health education for all individuals diagnosed with
active TB [19]. Specifically, the Ugandan MoH Guidelines for Tuberculosis Infection Control
state that “it is necessary to promptly initiate adequate TB treatment and support adherence
education to ensure completion of treatment for persons diagnosed with TB disease” [20]. No
specific guidance on the format of counseling (e.g. group vs. individual) is provided. The NTLP
has made education and counseling materials available through a partnership with USAID [21].
After diagnosis, patients return to the clinic for medication refills every two weeks for the first
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two months of treatment (the intensive phase) and every month for months three to six of
treatment (the continuation phase). The timeline of treatment from diagnosis to discharge is
outlined in Figure 1.

Participants
We considered consecutive adults (age ≥18) newly diagnosed with active TB for
inclusion into the study if they spoke English or Luganda and were diagnosed with drugsusceptible TB. A protocol for enrollment was established under the supervision of the KCCA
TB Unit Nurse In-Charge at Kisenyi Health Centre. Patients were referred to the study team by
any staff member in the TB unit once they were determined to be initiating TB treatment, either
as a result of positive GeneXpert testing, positive smear microscopy testing, or a clinical
diagnosis made by a trained clinician. All patients who were registered in the Uganda NTLP
Register as incident TB disease cases during the study period were considered eligible for
inclusion. We enrolled patients consecutively, with up to 5 new patients enrolled daily; the
research team decided a priori that it would not be feasible to conduct more interviews than this
in one day. We automatically excluded patients if they initiated treatment when the study team
was not present (outside of the hours of 9 a.m. to 4 p.m., Monday-Thursday), or if the TB unit
staff did not refer the patient to the study team before they received TEC. We also excluded
individuals if they transferred in from another health center, declined consent, were unable to
consent, or had immediate plans to transfer out to receive treatment at a different health center.
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Measurements
We collected data through audits of the treatment register and a survey that was verbally
administered by a Ugandan community health worker. Survey data were recorded into a
Qualtrics survey that was loaded onto an electronic tablet. The survey instrument is included in
Appendix A. Throughout the study period, we collected appointment attendance data and final
treatment outcomes from routine clinic registers.
We interviewed patients before they received routine TEC, collecting demographic and
clinical information as well as a baseline knowledge assessment. After the initial interview, the
patient received TEC, was given his or her first dose of medication, and was entered into the
NTLP Treatment Register. Before the patient left the clinic, we conducted a follow-up
knowledge assessment. Upon enrollment into the study, patients agreed to participate in 45minute follow-up interviews at three of their eight follow-up appointments (specifically, at two
weeks, two months, and five months). These interviews consisted of the knowledge assessment
and an adherence self-assessment. If a study participant missed an appointment, a member of the
study team called the patient to determine the reason they had not come to the clinic and, if
applicable, reminded them that the study interview would be completed at the next follow-up
visit. A schematic showing the timing of interviews is provided in Figure 1.

Survey Design
TB Literacy
We formulated the TB knowledge assessment to measure two major constructs: TB
disease-specific knowledge and TB treatment-specific knowledge. We used two sources to
formulate content domains for the assessment questions, with each source representing one of the
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major constructs. We adapted five disease-specific content domains utilizing TB counseling
guidelines published by Médecins Sans Frontières and learning objectives from the TB and HIV
Health Education Flipchart developed by USAID and the Ugandan MoH [21, 22]. These five
domains included (with shorthand in parentheses): Basics of TB (Microbiology), Warning signs
of TB (Warning signs), How TB is Spread (Transmission), Differentiation between TB and HIV
(TB vs HIV), and Preventing TB (Prevention) [21]. We adapted the treatment-specific content
domains from a rapid review of TB treatment literacy materials. [23]. In the review, the content
domains were developed utilizing concepts that had previously been identified as key enablers of
HIV treatment adherence. The three content domains under treatment-specific knowledge
include: How Treatment Works (e.g. patients understand that TB is curable and why adherence is
important), How to Take Medications (e.g. patients can describe the appearance of TB drugs,
length of treatment regimen, and side effect management), and Treatment Monitoring (e.g.
patients understand what interactions with the health system they should expect and how they
will know that treatment is working) [23]. We formulated individual questions in the assessment
to reflect the content elements listed in the rapid review. We excluded the following content
elements from the study’s assessment questions: “Explains why TB regimen includes multiple
drugs,” “States which TB drugs are in the patient’s regimen,” and “Lists the names of individual
TB drugs” [23]. TB drugs were administered in single tablets as a fixed-dose combination, so
these content elements would have been irrelevant to the assessment. A schematic of the TB
constructs and corresponding content domains used in the knowledge survey is provided in
Figure 2.
We designed the following scoring algorithm to aid in analyzing TB knowledge at three
hierarchical levels: construct, content domain, and individual component (question). We
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assigned each individual knowledge question to one of the eight content domains. There was an
uneven distribution of questions across the content domains. To give each content domain an
equal weight, we calculated the mean score for the questions answered correctly within each
content domain. We standardized the total score for the content domains within each construct
to a ten-point scale.
The first TB knowledge block consisted of closed-ended questions to which the only
possible answers were “yes” or “no.” The second block consisted of open-ended questions. For
these questions, we embedded decision rules into the survey questions to guide the interviewer in
choosing “correct” or “incorrect” based on the response given. Decision rule criteria were
initially composed of responses that members of the study team anticipated based on prior
experience or that respondents gave during pilot testing of the TB knowledge assessment. If
subjects gave new answers after initiation of the study, the study team agreed by consensus
whether to include that answer in the ‘correct’ or ‘incorrect’ criteria for that question. We made
this decision based on whether the response satisfactorily answered the question according to its
reason for inclusion in the assessment (referencing the objectives and domains stated above). The
study team then updated the response to include the new answer choice.
We specified scores greater than 90% as indicative of an adequate level of knowledge,
whether at the construct, content domain, or individual component level. We set this operational
definition of “adequate knowledge” to ensure that quality education had been administered. We
selected a relatively high cutoff because each of these areas has been defined to be important in
influencing TB treatment adherence and treatment completion. Our ultimate goal is the design
of an intervention that delivers patient-centered care in which a patient understands the causes

36

and treatments for his or her illness. Ideally, patients would understand each of these knowledge
components after receiving TEC.

TB Medication Adherence
We measured medication adherence in the survey through a self-assessment of
nonadherence over the past 7 days. Previous evaluations of self-report methods have shown that
this measure is a valid proxy for other adherence measures and can significantly predict clinical
outcomes [24]. The self-assessment measures were taken at each of the three follow-up
interviews, so analyses of association with nonadherence were conducted relative to each of the
three measures. In addition, multiple possible explanations for nonadherence were surveyed
(heretofore described as “difficulties with treatment”). We adapted the self-assessment questions
from a tool used in an isoniazid preventive therapy (IPT) implementation study in South Africa
[25].

Final Treatment Outcome
We defined final treatment outcome as a binary variable and coded WHO outcomes
associated with treatment success (cured, treatment completed) as treatment completed and other
WHO outcomes (died, treatment failed, and lost-to-follow-up) as treatment not completed [26].

Pilot Testing
Prior to initiation of study enrollment, we pilot tested each block of the assessment tool
with patients already receiving treatment at Kisenyi Health Centre. Pilot testing was carried out
by a Ugandan community health worker and included 12 patients. We revised questions if they
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were determined to be difficult for patients to understand or vulnerable to misinterpretation. We
tested different question types for each block to determine which method provided the most
variance in patient responses. We timed each block and designed the final assessment tool used
for the study to take no more than 45 minutes.
For the adherence self-assessment, we tested a Likert scale through which patients were
asked to rate their adherence to medications since their last appointment. There was little
variance in the answers given, with almost every respondent rating their adherence as “very
good” or “excellent.” In an effort to increase variance, we adapted the self-assessment to ask
patients to estimate the number of days in the past week that doses were taken late or missed.

Analysis
We sought to answer four distinct questions in the analysis: (1) is routine TEC effective
in increasing patients’ TB-specific knowledge; (2) is knowledge gained from TEC retained
throughout treatment; (3) is TB-specific knowledge associated with TB treatment nonadherence;
and (4) is TB-specific knowledge associated with final treatment outcomes? We used STATA
14.1 (Stata Corporation, College Station, Texas) for all analyses. We conducted bivariate
statistical tests at a significance level of p<0.05 and multivariate statistical tests at a significance
level of p<0.20.

Effect of Routine TEC on TB Knowledge
We analyzed the difference in TB knowledge before and after each patient received TEC
at three levels: construct, content domain, and knowledge component. For the constructs and
content domains, we analyzed the differences in proportion of correct answers before and after
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TEC using two-sided dependent t-tests. The null hypothesis was that there was no difference in
the proportion of correct answers before and after TEC. For the individual questions, we
compared the proportion of correct answers before and after TEC through McNemar’s test. The
null hypothesis was that the question was answered correctly at the same rate before and after
TEC.

TB Knowledge Retention After Diagnosis
We analyzed retention of knowledge throughout each patient’s treatment period stratified
by construct (disease-specific and treatment-specific knowledge) and relative to the post-test at
three time points after diagnosis: two weeks, two months, and five months. We analyzed the
differences in proportion of correct answers using two-sided dependent t-tests. We compared the
follow-up assessment results to the post-test to measure the extent to which within-patient
knowledge was retained after receiving TEC.

Association Between TB Knowledge and Treatment Outcomes
We used Poisson regression models to describe the association between independent
variables and TB treatment nonadherence. We conducted bivariate tests of association for the
two knowledge constructs and each of the eight content domains using the post-test scores at
diagnosis. We used the post-test scores because we found a general retention of knowledge from
the post-test to each of the three follow-up time points. We also conducted bivariate tests of
association for various demographic and clinical measures, including those that have been shown
to be associated with adherence and TB outcomes. Factors previously shown to be associated
with treatment outcomes include gender, age, HIV status and education level [3]. Additionally,
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we examined bivariate associations with various intermediate treatment measures (e.g. number
of late appointments and surveyed difficulties with treatment).
We used logistic regression models to describe the association between independent
variables and final treatment outcome. We conducted bivariate tests of association between final
treatment outcome and TB knowledge (at the level of constructs and content domains) and
relevant demographic and clinical measures. We did not include patients who either transferred
out of Kisenyi for treatment after enrolling into the study or had not yet completed treatment by
March 1, 2019 in these analyses.
We used a multivariate Poisson regression model to estimate the adjusted relative risk of
nonadherence and a multivariate logistic regression model to estimate the adjusted odds of
treatment completion with increasing scores for individual knowledge content domains. We
considered demographic and clinical variables for inclusion into the model if they have
previously been shown to influence nonadherence or treatment completion or showed significant
bivariate associations with the outcome. We did not consider variables for inclusion into the
models if they could be considered intervening variables, as adjusting for these variables may
have dominated the effect we intended to explore with the knowledge components. These
variables included the various difficulties with treatment and the number of appointments
attended late. After conducting bivariate tests of association, we included any variable into the
model that showed an association at p<0.20. We used backward selection to remove
nonsignificant variables.
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Human Subjects
All patients provided written informed consent for participation. The study protocol was
approved by the Makerere College of Health Sciences, the Uganda National Council for Science
and Technology, and the Yale University Human Investigation Committee.
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Results
Patients were recruited if they initiated treatment between June 5, 2018 and August 15,
2018. We enrolled a total of 80 patients during this period. The results of study enrollment are
provided in Figure 3. The cohort was comprised of 28% female participants (n=22), 36% people
living with HIV (n=29), and 30% who had experienced a prior TB disease episode (n=24). TEC
was administered as part of a group for 54% of patients in the cohort. The USAID/MoH
Educational Flipchart was used as a visual aid to supplement TEC for 56% of patients in the
cohort. A summary of the study participants’ characteristics is provided in Table 1.
Of the 80 subjects initially enrolled, two were lost to follow-up after the initial interviews
at diagnosis because they elected to transfer out to receive treatment at another health center.
They are included in analyses of within-patient change in knowledge before and after TEC but
have been excluded from analyses involving nonadherence measurements and treatment
outcomes.

Effect of Routine TEC on TB Knowledge
The mean TB disease-specific knowledge score at baseline was 61%, with baseline
content domain scores ranging from 47% to 77%. Overall, there was a mean within-subject
increase of 16% (95% CI: 12%-19%, p<0.0001) after TEC. There were modest but statistically
significant within-subject increases across each of the five disease-specific content domains. In
descending order of the magnitude of increases, knowledge related to ‘Prevention’ increased by
35% (95% CI: 22%-48%, p<0.0001); ‘Microbiology’ increased by 16% (95% CI: 8.2%-23%,
p=0.0001); ‘Transmission’ increased by 14% (95% CI: 7.7%-21%, p<0.0001); ‘Warning Signs’
increased by 8.5% (95% CI: 3.2%-14%, p=0.002) and ‘TB vs HIV’ increased by 7.3% (95% CI:
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1.9% to 13%, p=0.009). After TEC, the mean TB disease-specific knowledge score was 76%,
with content domain scores ranging from 65% to 85%.
The mean TB treatment-specific knowledge score at baseline was 42%, with content
domain scores ranging from 20% to 72%. Overall, there was a mean within-subject increase of
40% (95%CI: 36%-44%, p<0.0001) after TEC. There were statistically significant withinsubject increases across each of the three treatment-specific content domains. In descending
order of the magnitude of increases, ‘Treatment Monitoring’ increased by 54% (95% CI: 47%62%, p<0.0001); ‘How to Take Medications’ increased by 42% (95% CI: 37%-47%, p<0.0001);
and ‘How Treatment Works’ increased by 24% (95% CI: 20%-29%, p<0.0001). After TEC, the
mean TB treatment-specific knowledge score was 82%, with content domain scores ranging
from 74% to 96%. The mean pre-test and post-test scores, 95% confidence intervals and mean
within-subject difference between pre- and post-test scores for each TB disease-specific and
treatment-specific content domain are provided in Table 2. Figure 3 provides a bar graph
depicting the pre- and post-test scores for each of the eight content domains.
Out of 17 disease-specific knowledge questions, the score on 9 questions changed
significantly before and after TEC. Seven of the 17 questions were answered with a mean score
greater than 90% on the post-test, representing an adequate level of knowledge. Of the 9
questions that showed a statistically significant improvement, 4 had mean post-test scores above
90%, and each of these questions had pre-test scores in the range of 80%-90%. There were 5
questions that showed no statistically significant improvement and had post-test means that were
in the range of 41%-64%. These questions pertained to either TB transmission or warning signs.
In Figure 5, the pre- and post-test score for each disease specific knowledge question are
provided in a bar graph, in ascending order of the post-test score. Questions are grouped into
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three blocks: (1) those with a pre- and post-test score below 90%, (2) those with a pre-test score
below 90% but a post-test score above 90%, and (3) those with a pre- and post-test score above
90%.
Out of 13 treatment-specific knowledge questions, the score on 11 questions changed
significantly before and after TEC. Seven of the 13 questions were answered with a mean score
less than 90% on the post-test. Notably, out of three questions assessing patients’ knowledge of
potential treatment side effects and how to manage them, none reached a post-test score above
65%. Additionally, only 54% of patients knew how long it would take them to feel better after
initiating treatment (compared to 31% at baseline). Figure 6 provides a bar graph of scores for
each individual treatment-specific question, grouped in the same set of blocks as Figure 5. The
mean scores on the pre- and post-test for each individual question, along with each question’s pvalue for the McNemar’s test, are provided in Tables 3 (disease-specific knowledge questions)
and 4 (treatment-specific knowledge questions).
Overall, 11% of patients had post-test scores above 90% for disease-specific knowledge,
and 35% of patients had post-test scores above 90% for treatment-specific knowledge.

TB Knowledge Retention after Diagnosis
TB disease-specific knowledge did not significantly change relative to the post-test at two
of the three follow-up interviews, and TB treatment-specific knowledge did not significantly
change relative to the post-test at any of the follow-up interviews. For disease-specific
knowledge, the change was -1.2% (95% CI: -5.1% to +2.7%, p=0.54) at two weeks; -10% (95%
CI: -15% to -5.6%, p<0.0001) at two months; and -2.9% (95% CI: -7.1% to +1.3%, p=0.17) at
five months. For treatment-specific knowledge, the change was +2.6% (95% CI: -2.5% to
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+7.7%, p=0.31) at two weeks; -3.0% (95% CI: -7.6% to +1.5%, p=0.19) at two months; and 3.6% (95% CI: -8.7% to +1.4%, p=0.15) at five months. The results of the dependent t-tests for
within-subject differences in means for the disease-specific and treatment-specific knowledge
constructs are provided in Table 5.

Association Between TB Knowledge and Treatment Nonadherence
The mean number of pills late or missed in the last week was 2.1 at two weeks, 1.2 at two
months, and 0.78 at five months. Table 6 displays the mean number of days of self-reported
nonadherence over the last week and the proportion of patients who reported missing each
possible value (range=0-7) at each time point. A summary of the mean percentage of “yes”
answers for the questions assessing difficulties with treatment at each of the time points is
provided in Table 7.
None of the previously-established risk factors for nonadherence showed bivariate
associations with nonadherence in this cohort. However, at two months, patients who reported
having TB before the current episode were 57% less likely to report nonadherence than patients
experiencing their first TB episode (RR=0.43, 95% CI 0.23-0.77, p=0.05). The results of the
bivariate Poisson regression analyses for demographic and various clinical variables are provided
in Table 9.
The results for the bivariate tests of association with each knowledge element are
provided in Table 8. Each of the knowledge constructs (disease-specific and treatment-specific
knowledge) was significantly associated with nonadherence at two weeks and two months, but
not at five months. For each 10% increase in disease-specific knowledge score, nonadherence
decreased by 14% at two weeks (RR=0.86, 95% CI 0.76-0.98, p=0.021) and 18% at two months
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(RR= 0.82, 95% CI 0.67-0.97, p=0.022). For each 10% increase in treatment-specific
knowledge score, nonadherence decreased by 12% at two weeks (RR=0.88, 95% CI 0.80-0.97,
p=0.010) and 20% at two months (RR=0.80, 95% CI 0.70-0.90, p<0.0001).
Among the eight content domains, at least two were significantly associated with selfreported nonadherence at each time point. Increasing score in “Transmission” knowledge was
associated with decreasing rates of nonadherence at both two weeks (RR=0.92, 95% CI 0.850.98, p=0.011) and two months (RR=0.87, 95% CI 0.79-0.97, p=0.009). The same relationship
was observed with knowledge related to “How to take medications” at two weeks (RR=0.90,
95% CI 0.84-0.96, p=0.001) and two months (RR=0.89, 95% CI 0.81-.97, p=0.010). At two
months, increasing score in knowledge related to “Treatment monitoring” was significantly
associated with decreasing rates of nonadherence (RR=0.88, 95% CI 0.81-0.94, p=0.001); this
relationship was not observed at two weeks. Each of these content domains were no longer
significantly associated with nonadherence at five months. At this point in treatment, for each
10% increase in score for the domain “Warning Signs,” nonadherence decreased by 13%
(RR=0.87, 95% CI 0.76-0.99, p=0.035), but for each 10% increase in score for the domain “How
treatment works,” nonadherence increased by 82% (RR=1.8, 95% CI 1.0-3.8, p=0.045).
Various intermediate treatment-related variables showed significant associations with
nonadherence at each of the three time points. At five months, for each appointment that a
patient had attended late (at least one day past their scheduled appointment date), he or she was
59% more likely to report nonadherence (RR=1.6, 95% CI 1.3-2.0, p<0.0001). In addition,
multiple surveyed “difficulties with treatment” were significantly associated with nonadherence.
For example, patients who had difficulty taking medication at specified times were more likely
to report nonadherence at two weeks (RR 1.8, 95% CI 1.3-2.5, p=0.001), two months (RR 3.5,
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95% CI 2.3-5.4, p<0.0001), and five months (RR 2.3, 95% CI 1.2-4.5, p=0.02). In addition,
patients who reported feeling worse after taking their medication were more likely to report
nonadherence at two weeks (RR 2.01, 95% CI 1.46-2.76, p<0.0001) and two months (RR 1.62,
95% CI 1.02-2.58, p=0.04), but this association was no longer observed at five months.

The

results of the bivariate Poisson regression analyses for intermediate treatment-related variables
are provided in Table 9.
The adjusted relative risks for variables in the final multivariate Poisson regression
models at each of the three time points are provided in Table 10. At two weeks, nonadherence
decreased by 9% for each 10% increase in “How to take medications” score and 7% for each
10% increase in “Transmission” score, after adjusting for HIV status. At two months,
nonadherence decreased by 10% for each 10% increase in “How treatment works” score and 8%
for each 10% increase in “Transmission” score after adjusting for previous TB status and type of
counseling received (group vs. individual). At five months, nonadherence decreased by 12% for
each 10% increase in “Microbiology” score and 18% for each 10% increase in “TB vs HIV”
score, but increased by 20% for each 10% increase in “Warning signs” score and 58% for each
10% increase in “How treatment works” score after adjusting for sex.

Association Between TB Knowledge and Final Treatment Outcome
We closed data collection on March 1, 2019. As of this date, 49 patients (68%) were
classified as “Completed Treatment” and 23 patients (32%) were classified as “Did Not
Complete Treatment.” Notably, both patients who died were living with HIV when they initiated
TB treatment. Detailed frequencies of patients in each classification are provided in Table 11.
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We removed 8 patients from the analysis because they either transferred out after enrollment or
did not have an outcome at the time that data collection closed.
None of the previously-established risk factors for nonadherence (sex, age, HIV status
and education level) were significantly associated with final treatment outcome. Across all
knowledge elements (both constructs and content domains), none showed significant bivariate
associations with final treatment outcome. After adjusting for sex and type of counseling
received (group vs. individual), patients had increased odds of completing treatment for each
10% increase in score on the “Transmission” content domain (OR=1.2, 95% CI: 0.94-1.5,
p=0.16). Among the intermediate treatment measures, “number of late appointments” showed a
statistically significant bivariate association with final treatment outcome (OR=0.69, 95% CI
0.50-0.96, p=0.03).
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Discussion
TEC is a universally recommended adherence intervention for patients initiating
treatment for active TB. Previous studies have demonstrated that education and counseling
interventions play an important role in decreasing default rates and increasing adherence,
treatment completion, and cure rates [8-10]. In this study, we sought to evaluate the
effectiveness of routine TEC at a high-enrolling TB clinic and determine which specific TB
knowledge domains are important in influencing medication adherence and treatment
completion.
To our knowledge, a standardized, validated TB knowledge assessment for patients
initiating TB treatment does not exist. We developed an instrument to measure domains of TB
knowledge that have previously been indicated to be of importance in a TEC intervention [2123]. We did not conduct a comprehensive instrument validation process, as this was outside the
scope of the project. However, before implementing the knowledge questionnaire, we
established face validity by having the questions reviewed by multiple parties; members of the
Ugandan research team reviewed both English and Luganda versions of the instrument to assess
question difficulty and consistency after translation, and a member of the U.S. research team
with a background in survey validation reviewed individual questions to check for errors that
could lead to bias. We also conducted a pilot test of the questionnaire with a group of
participants totaling 15% of the intended sample size.
This study showed that routine TEC resulted in a statistically significant increase in
knowledge across the eight surveyed content domains. However, none of the content domain
means increased to a level reflective of high-quality education, revealing a need for improvement
in the delivery of routine TEC. Both disease-specific and treatment-specific knowledge
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increased after TEC and were generally retained at the two-week, two-month and five-month
follow-up appointments. This retention was seen to a greater extent statistically for treatmentspecific knowledge compared to disease-specific knowledge. This discrepancy might be
explained by the statistical artifact of higher baseline scores for disease-specific knowledge,
making the minimum detectable effect size smaller. Further, the magnitudes of the mean withinsubject changes in score at each follow-up appointment are similar for both disease-specific and
treatment-specific knowledge, suggesting that knowledge was retained to the same extent for
both constructs (Table 5).
There were general patterns of heterogeneity at the individual question level. Scores
varied based on baseline knowledge level; the extent to which scores increased after TEC; and
whether the post-test score reflected an adequate level of knowledge (Figures 5 and 6). This
suggests an importance for analyses related to TB knowledge to describe and account for this
granular complexity.
Adherence is known to be an important predictor of TB treatment outcomes, but less is
known about what factors predict adherence. This study showed that some content domains of
TB knowledge may be more important than others in influencing medication adherence. This
finding builds on previous facility-based studies that showed associations between unsatisfactory
TB knowledge and both delay in initiating treatment and defaulting from treatment early [15,
27]. Our findings identify specific knowledge components that might help predict adherence.
For example, higher scores on questions related to both “Transmission” and “How to take
medications” were significantly associated with decreased nonadherence at both two weeks and
two months. A recent study showed that missing even one pill per week resulted in double the
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risk of unfavorable outcomes [5]. Improvements in TB knowledge could provide an effective
avenue for improving adherence and, potentially, treatment outcomes.
Our finding that routine TEC was effective in increasing TB knowledge is in line with a
cross-sectional study in Vietnam that sought to evaluate routine TEC delivered at TB clinics
[16]. Our study was strengthened by the paired, pre/post design at diagnosis, as this allowed for
analysis of within-patient increase in knowledge through dependent t-tests and increased our
power. We also found that knowledge was retained throughout treatment. This differs from the
results of a previous cross-sectional study in Ethiopia that compared knowledge scores among
patients in different phases of treatment and found that patients in the intensive phase of
treatment had a four-fold risk of poor knowledge compared to patients in continuation phase
[14]. Measurement of each individual patient’s TB knowledge at diagnosis and throughout
treatment is a strength of our study design, as it provided more power and precision and allowed
for a clear analysis of retention from diagnosis to multiple points in the treatment cascade.
TB medication adherence is important in reducing treatment relapse, treatment failure,
drug resistance and death. Individual-level predictors of adherence must be understood when
designing behavior change interventions to improve adherence. Our findings suggest that
specific content domains of TB knowledge may play an important role in encouraging adherence
and, once identified, could be targeted through specific behavior change techniques as a part of
routine TEC. The process followed in this study could be utilized at other health facilities as a
potential quality improvement tool to identify areas in patient knowledge that need more focus.
Once these areas have been identified, specific changes could be implemented to TEC at the
facility that could significantly improve treatment outcomes. For example, we found that higher
scores in “How to take medications” resulted in lower rates of nonadherence at multiple time
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points in treatment, and that multiple questions assessing knowledge of side effects within this
domain had low post-test scores. This suggests that there could be an opportunity to improve
delivery of TEC in this setting as it relates to side effect management, and making this
improvement could directly reduce nonadherence later in treatment.
While our study design had a number of strengths, there were some notable limitations.
The pre/post nature of the knowledge assessment at diagnosis may have resulted in a greater
increase in knowledge than would have occurred had there been no pre-test; if there were
questions on the pre-test that patients did not know, they may have focused in on these areas
during TEC, knowing that they would be asked the same questions on the post-test. We were
unable to follow up with a number of patients who had been classified as “lost to follow up” to
discern their actual outcomes. We classified these patients as “Did not complete treatment,” per
WHO guidelines. There is a chance that these patients transferred to another clinic and actually
completed treatment, which would have resulted in non-differential misclassification of the
outcome and a bias of the effect size toward the null. If this did occur, our results would be an
underestimate of the true effect size.
The modest size of our study may have limited the ability to detect a statistically
significant association between knowledge domains and treatment completion. Additionally, our
nonadherence measure relied on self-report; this method could have been subject to social
desirability bias, where patients who actually experienced a nonzero number of nonadherent days
reported a lower number when asked this question. Finally, we designed our study to focus on
individual-level predictors of nonadherence and treatment completion, but there are several
potential structural barriers that also could have influenced these outcomes, including distance to
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the clinic; absence of health workers to administer medication; and competing obligations with
work or family.
There is a need for a standardized, validated TB knowledge survey that can be used to
measure TB knowledge among patients initiating and receiving treatment for active TB. Other
studies have found that TB knowledge in the community and among new TB patients varies
based on a number of factors, including geographic region [14-16, 27]. Each of these studies
measured knowledge with an original questionnaire and measured a range of domains through a
variety of open and closed-ended questions [14-16, 27]. Because of this variation, it is difficult
to compare results among these studies. A standardized assessment will be necessary to advance
scientific understanding of TB knowledge among this population and design effective adherence
interventions.
The source population from which the cohort was sampled has a higher HIV prevalence,
a lower average socioeconomic status, and higher rates of adverse treatment outcomes relative to
the rest of Kampala. Because of this, a multi-center study in a variety of settings is needed to
determine which of our study’s findings, if any, are generalizable to the general population. A
larger sample size is necessary to increase power to detect an association between TB knowledge
and final treatment outcome. Future studies should measure other individual-level predictors of
adherence such as stigma and treatment intentions to better understand how these factors operate
concurrently with knowledge in determining adherence and treatment outcomes.
This study was developed with the intention of informing the development of a tailored,
patient-centered TEC intervention. Guidelines published by Médecins Sans Frontières will be
used as a basis for intervention development [22]. The intervention will involve task shifting of
TEC from nurses and CHWs to “expert clients,” members of the community who have already
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experienced TB treatment and are trained in delivering peer education and counseling. Through
a “prompt card,” expert clients will provide TEC with a standardized list of questions that should
be addressed through counseling in order to influence key target behaviors, including daily
adherence and completing treatment. The results from this study have informed this list, and
specific behavior change techniques will be employed to address the areas we have identified to
be important predictors of treatment adherence. For example, expert clients will educate patients
about common side effects, and then counsel them on the salience of consequences if various
side effects are not correctly handled. After receiving all of the necessary health education
points, expert clients will work with patients to develop an individualized adherence plan. The
results of our study suggested that there are common individual-level difficulties with treatment
that need to be addressed through counseling, such as taking medication at specified times. Our
hypothesis is that interventions tailored to meet individual patient needs as implemented through
an individualized adherence plan are more likely to lead to successful treatment outcomes than
simply providing knowledge alone.
Our study found that routine TB education and counseling was effective at increasing
patient knowledge at a high-enrolling TB clinic in Kampala, and this knowledge was generally
retained throughout multiple time points of treatment. In this cohort, specific content areas of
TB knowledge were significantly associated with medication nonadherence later in treatment.
Given these findings and the importance of adherence on TB treatment completion, as well as the
likely modest cost of making targeted improvements to TEC, this is an area that warrants further
study and investment.
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Appendices
Appendix A. Questionnaire
Respondent Information
1. Treatment initiation date
2. NTLP Register Number
3. Sex
4. Date of birth
5. What is the highest level of education you have completed?
6. What is your current occupation?
7. Referred to the TB unit from…
8. Did you receive TEC before coming to the TB unit for this TB episode?
9. What is your HIV status?
10. Have you ever had TB before?
11. Has someone in your household or anyone close to you had TB?
12. Have you ever received any information about TB?
a. If yes, where have you received information about TB?
i. Religious leaders (Yes/No)
ii. Health workers (Yes/No)
iii. Family and friends (Yes/No)
iv. Teachers (Yes/No)
v. Brochures, posters or other printed materials (Yes/No)
vi. Media (Yes/No)
TB Knowledge: Closed-Ended Questions (Content Domain in parentheses)
TB attacks the lungs. (Microbiology)
TB can attack other parts of the body outside of the lungs. (Microbiology)
Everyone who is exposed to TB germs becomes ill. (Microbiology)
Answer “yes” if the condition is a warning sign of TB and answer “no” if it is not a
warning sign of TB. (Warning signs)
a. A cough that does not go away for two weeks
b. Loss of weight
c. A cough that goes away after a few days
d. General weakness
e. Vomiting
5. Answer “yes” if the statement is a way that TB can be spread and answer “no” if TB
cannot be spread that way. (Transmission)
a. Through drinking water
b. Through the air
c. Through food
6. Unprotected sex can spread TB. (TB vs. HIV)
7. If you stop treatment before the full course of therapy, your TB becomes harder to cure.
(How treatment works)
1.
2.
3.
4.
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TB Knowledge: Open-Ended Questions + Decision Logic (Content Domain in parentheses)
1. How often can TB be cured if treatment is started in time? (How treatment works)
a. Correct (always, almost always, "I am pretty sure TB can be cured if you
complete treatment")
b. Incorrect (never, sometimes, doesn’t know)
2. How are TB germs released? (Transmission)
a. Correct (when a person with TB coughs, sneezes, spits)
b. Incorrect (when a person with TB vomits, touches you; if you share a cup or food
with someone who has TB; doesn't know)
3. If you breathe in TB germs, where do they settle and grow? (Transmission)
a. Correct (lungs)
b. Incorrect (anywhere else, doesn’t know)
4. Can you have HIV only (without TB)? (TB vs. HIV)
a. Correct (yes)
b. Incorrect (no, doesn’t know)
5. Can you have TB only (without HIV)? (TB vs. HIV)
a. Correct (yes)
b. Incorrect (no, doesn’t know)
6. How can you stop the spread of TB? (Prevention)
a. Correct (cover mouth with a handkerchief; cover mouth when coughing; avoid
others for the first two weeks of treatment; don't go out in public for the first two
weeks of treatment; don't spit on the ground in public)
b. Incorrect (tell everyone that I have TB; interviewer uses judgement; doesn't
know)
7. If you have TB, how long do you take the medication? (How to take medications)
a. Correct (until you are discharged, 6-8 months; when they test me again and there
is no more TB and the nurse tells me I can finish treatment)
b. Incorrect (any other answer, doesn’t know)
8. When can you stop taking the TB medication? (How treatment works)
a. Correct (when you finish the full course of therapy, when you are discharged,
after 6-8 months)
b. Incorrect (when the cough stops, when you feel better, doesn't know
9. If you stop taking the TB medication before the treatment period is finished, what might
happen? (How treatment works)
a. Correct (the germs won't be fully killed and another TB episode can occur; the
germs can develop resistance; you can die; you can end up taking the medication
for a longer period of time)
b. Incorrect (nothing, doesn’t know)
10. Name two potential side effects of TB treatment. (How to take medications)
a. Correct (skin rash, nausea, joint pain, color of urine changes, etc.—interviewer
uses judgment)
b. Incorrect (interviewer uses judgment; can only name one; doesn’t know)
11. What should you do if your TB medication gives you nausea? (How to take medications)
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a. Correct (endure for a few weeks, try taking medication with food or other selfmedication such as lemon)
b. Incorrect (stop taking medication, come to the clinic, doesn't know)
12. What should you do if your TB medication gives you joint pain? (How to take
medications)
a. Correct (take pain killers, take pyridoxine, move around and do some light
exercises, reduce on doing heavy work)
b. Incorrect (stop taking medication, come to the clinic, doesn’t know)
13. What should you do if your TB medication gives you yellow or red eyes, too much
vomiting, intense body rash, or issues with sight? (How to take medications)
a. Correct (talk to a health worker, come to the clinic)
b. Incorrect (stop taking medication, sleep it off, nothing, doesn’t know)
14. When should you come to the clinic for your next appointment? (Treatment monitoring)
a. Correct (be able to say the date or the amount of time until the next appointment)
b. Incorrect (when the health worker tells me to come back; can’t tell the date or the
amount of time until the next appointment; doesn’t know)
15. What do your TB medications look like? (How to take medications)
a. Correct (adequately explains what pills look like in color and shape)
b. Incorrect (incorrectly explains what the pills look like; doesn’t know)
16. When do you take your TB medications? (How treatment works)
a. Correct (in the morning when you first wake up)
b. Incorrect (any other time; multiple times throughout the day; doesn’t know)
17. After taking the medication, how long does it usually take to start feeling better?
(Treatment monitoring)
a. Correct (any amount of time between 2 weeks and 1 month)
b. Incorrect (any time outside of 2 weeks and 1 month; doesn’t know)
Self-Reported Nonadherence
1. During the last week, how many days were you late or missed taking your TB
medication?
2. Below are some reasons why people have difficulty taking their drugs. Answer "yes" or
"no" to indicate whether or not each of the following reasons describes why you may
have had difficulty taking your drugs in the last 7 days.
a. I feel worse when I take the pills
b. There are too many pills to take
c. I forget to take the pills
d. I ran out of pills
e. I don’t think I need the pills
f. I was away from home
g. I did not want others to notice
h. I am too busy
i. I had problems taking pills at specified times
j. I was confused or uncertain about how to take the pills
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